# An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

> **NCT02969265** · PHASE3 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** TCV-116CCB
- **DRUG:** Amlodipine Placebo
- **DRUG:** TCV-116CCB Placebo

## Key facts

- **NCT ID:** NCT02969265
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05-09
- **Primary completion:** 2018-07-12
- **Final completion:** 2018-07-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business reasons unrelated to product safety
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02969265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02969265, "An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02969265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*